XBiotech Inc.
NASDAQ:XBITBiotechnology
-$0.02 today
- Market cap
- $52.74M
- Beta
- 0.84
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.32
Volume 0.06M
Average 0.03M
XBIT Total Non-current Liabilities
All obligations due after more than one year.
XBiotech Inc.NASDAQ: XBIT
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 4.5% from a year ago
Total non-current liabilities stood at $1.82M at the end of Q1 FY2026, up 4.5% from a year earlier and up 0.9% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.
Context
- Total non-current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
- Total non-current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +4.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.8M USD
- Year-over-year change
- +4.8%
- 4-year CAGR
- -6.3%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.8M | +4.8% |
| FY2024 | 2024-12-31 | 1.72M | +3.1% |
| FY2023 | 2023-12-31 | 1.67M | +2.1% |
| FY2022 | 2022-12-31 | 1.64M | -30.1% |
| FY2021 | 2021-12-31 | 2.34M | — |
Total Non-current Liabilities vs competitors
How XBIT compares with its peers on the latest reported figures
- XBIT's Mar 2026 total non-current liabilities of $1.82M is the 6th highest of the 9 companies compared; the peer median is $7.38M.
- Its year-over-year change of +4.5% is the 3rd highest of 9, against a peer median of -12.9%.
- Total non-current liabilities amounts to 1.3% of total assets for XBIT, versus a peer median of 5.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $85.1M | -8.2% | +1.8% | 42.1% | |
| Mar 2026 | $51.11M | -28.9% | -14.2% | 14.3% | |
| Dec 2025 | $17.74M | +3070.2% | +7.6% | 22.7% | |
| Mar 2026 | $11.02M | -17.6% | -14.6% | 6.5% | |
| Mar 2026 | $3.74M | +49714.6% | — | 1.6% | |
| Mar 2026 | $1.82M | +4.5% | +3.3% | 1.3% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.26M | -47.6% | -28.7% | 1.2% |
| Mar 2026 | $844.91K | +3.6% | -6.3% | 4.5% | |
| Apr 2026 | $70.18K | -43.3% | -14.5% | 1.0% | |
| Peer median (excluding XBIT) | $7.38M | -12.9% | -14.2% | 5.5% | |
Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 236.98M | 157.31M | 200.02M | 172.68M | 125.55M |
| Short-term Investments | 0 | 60.17M | 0 | 0 | 0 |
| Net Receivables | 8.95M | 1.76M | 935K | 858K | 360K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 601K | 760K | 1.03M | 1.04M |
| Total Current Assets | 246.87M | 219.84M | 201.72M | 174.57M | 126.95M |
| Property, Plant & Equipment (Net) | 28.31M | 26.26M | 24.9M | 24.53M | 23.13M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 1.09M | 1.66M | 0 | 0 | 0 |
| Other Non-current Assets | (1.09M) | (1.66M) | 0 | 0 | 0 |
| Total Non-current Assets | 28.31M | 26.26M | 24.9M | 24.53M | 23.13M |
| Total Assets | 275.18M | 246.1M | 226.62M | 199.09M | 150.08M |
| Account Payables | 2.07M | 2.41M | 2.52M | 2.22M | 1.54M |
| Short-term Debt | 0 | 0 | 0 | 10.25M | 0 |
| Tax Payables | 10K | 55K | 83K | 1.72M | 76K |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 904K | 1.17M | 562K | 611K | 5.18M |
| Total Current Liabilities | 3.45M | 4.07M | 6.1M | 15.11M | 7.93M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 873K | 59K | 0 | 0 | 5K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 1.47M | 1.58M | 1.67M | 1.72M | 1.8M |
| Total Non-current Liabilities | 2.34M | 1.64M | 1.67M | 1.72M | 1.8M |
| Total Liabilities | 5.79M | 5.7M | 7.77M | 16.83M | 9.73M |
| Common Stock | 262.26M | 267.33M | 271.15M | 273.11M | 276.73M |
| Retained Earnings | 5.15M | (27.75M) | (52.31M) | (90.84M) | (136.38M) |
| Accumulated OCI | 1.97M | 826K | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 269.39M | 240.4M | 218.85M | 182.27M | 140.35M |
| Total Debt | 0 | 0 | 0 | 10.25M | 0 |
| Net Debt | (236.98M) | (157.31M) | (200.02M) | (162.43M) | (125.55M) |
XBiotech Inc.
NASDAQ:XBIT
Intrinsic Alpha fair value
Locked
Current Price
$1.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.